Exelixis (EXEL) Non-Current Assets (2010 - 2026)
Exelixis (EXEL) recorded quarterly Non-Current Assets of $1.4 billion in Q2 2026, down 1.15% quarter-over-quarter from $1.4 billion in Q1 2026, and down 3.87% on a YoY basis from $1.4 billion in Q2 2025.
Exelixis (EXEL) Non-Current Assets (2010 - 2026) Analysis & Trends
Exelixis' Non-Current Assets history runs 17 years deep, the most recent figure standing at $1.4 billion for Q2 2026.
- In Q2 2026, Non-Current Assets fell 3.87% year-over-year to $1.4 billion; the TTM figure through Apr 2026 stood at $5.7 billion (up 1.38% YoY), while the FY2026 annual figure was $1.4 billion, down 5.34% from the prior year.
- Non-Current Assets was $1.4 billion for Q2 2026 at Exelixis, down from $1.4 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.6 billion in Q4 2023 to a low of $811.4 million in Q2 2022.
- Historically, Non-Current Assets has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2025.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets jumped 85.89% in 2022, then declined 16.51% in 2024.
- A 5-year view of Non-Current Assets shows it stood at $1.5 billion in 2022, then rose by 11.82% to $1.6 billion in 2023, then decreased by 13.16% to $1.4 billion in 2024, then climbed by 0.76% to $1.4 billion in 2025, then decreased by 2.56% to $1.4 billion in 2026.
- The last three Non-Current Assets figures came in at $1.4 billion (Q2 2026), $1.4 billion (Q1 2026), and $1.4 billion (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 39.71 Mn |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | 1.38 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 1.38 Bn |
| Jan 2, 2026 | 1.40 Bn |
| Oct 3, 2025 | 1.42 Bn |
| Jul 4, 2025 | 1.50 Bn |
| Apr 4, 2025 | 1.44 Bn |
| Jan 3, 2025 | 1.48 Bn |
| Sep 27, 2024 | 1.41 Bn |
| Jun 28, 2024 | 1.30 Bn |
| Mar 29, 2024 | 1.51 Bn |
| Dec 29, 2023 | 1.62 Bn |
| Sep 29, 2023 | 1.53 Bn |
| Jun 30, 2023 | 1.55 Bn |
| Mar 31, 2023 | 1.51 Bn |
| Dec 30, 2022 | 1.45 Bn |
| Sep 30, 2022 | 1.12 Bn |
| Jul 1, 2022 | 1.03 Bn |
| Apr 1, 2022 | 811.38 Mn |
| Dec 31, 2021 | 781.49 Mn |
| Oct 1, 2021 | 785.71 Mn |
| Jul 2, 2021 | 774.03 Mn |